SCHEMBL26022134

SCHEMBL26022134

CC(C)Cc1cccc(NS(=O)(=O)C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.52
▸ PTGS1 P23219 2/20 0.47
▸ PTGS2 P35354 2/20 0.47
▸ CA1 P00915 1/20 0.45
▸ CYP3A4 P08684 3/20 0.43
▸ CYP2D6 P10635 3/20 0.43
▸ SLC6A2 P23975 3/20 0.43
▸ SLC6A4 P31645 3/20 0.43
▸ SLC6A3 Q01959 3/20 0.43
▸ PTPN11 Q06124 1/20 0.43
▸ KDM1A O60341 1/20 0.42
▸ PRMT6 Q96LA8 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ HTR6 P50406 1/20 0.41
▸ CYSLTR2 Q9NS75 1/20 0.41
▸ CYSLTR1 Q9Y271 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ IKBKB O14920 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19567186 0.83 PTGS1 (0.63) CA2PTGS1PTGS2CA1PTPN11
SCHEMBL10209790 0.81 NR3C1 (0.52) PTGS1SMN1; SMN2NR3C1
SCHEMBL23514767 0.81 CA2 (0.54) CA2PTGS1PTGS2CA1CYP3A4
SCHEMBL20782066 0.81 CA2 (0.54) CA2PTGS1PTGS2CA1CYP3A4
SCHEMBL31680271 0.80 CA2 (0.56) CA2PTGS1PTGS2CA1CYP3A4
SCHEMBL21986566 0.80 CA2 (0.56) CA2PTGS1PTGS2CA1CYP3A4
SCHEMBL9571373 0.80 CA2 (0.56) CA2PTGS1PTGS2CA1CYP3A4
Cyanide SCHEMBL28184922 0.77 CA1 (0.43) CA2CA1HTR6SMN1; SMN2IKBKB
SCHEMBL15836544 0.77 CA2 (0.52) CA2PTGS1PTGS2CA1CYP3A4
SCHEMBL12153756 0.74 CA2 (0.61) CA2PTGS1PTGS2CA1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731943-B2 Therapeutic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2023-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731943-B2 Therapeutic compounds, compositions and methods of use thereof JAK2, JAK1, JAK3 CA2 1031/4885PTGS1 624/4885PTGS2 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback